search for


Pharmaceutical GMP Inspection: Case Study of USA and EU
Yakhak Hoeji 2019;63(1):15-23
Published online February 28, 2019
© 2019 The Pharmaceutical Society of Korea.

Eunmi Ban*, Dong-Jin Jang**, Taek-Hyun Kwon*, and Aeri Kim*,#

*College of Pharmacy, CHA University **Department of Pharmaceutical Engineering, Inje University
Correspondence to: Aeri Kim, College of Pharmacy, CHA University, 521 CHA Bio Complex, 335 Pangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, Korea, Tel: +82-31-881-7166, Fax: +82-31-881-7219, E-mail:
Received November 1, 2018; Revised January 7, 2019; Accepted January 7, 2019.
The Korea’s Ministry of Food and Drug Safety (MFDS) became a member of PIC/S in 2014, which would promote the Korean pharmaceutical companies produce reliable quality medicines with global standard. Therefore, the MFDS has been conducting continuous efforts for revising regulatory requirements including GMP inspection according to PIC/S GMP guideline. In this study, we have investigated databases of GMP inspection reports by the regulatory agencies of USA and EU, and analyzed GMP inspection deficiencies, including warning letters by US FDA and non-compliance reports by EU. We have found out that the outcomes of GMP inspections are made available online by both the USA and EU regulatory agencies to the regulators, the pharmaceutical company and the public. In addition, among various observed GMP deficiencies, quality control or management and documentation have been the most frequently observed differences, suggesting that these items should be carefully evaluated and managed in the manufacture of pharmaceutics. The results will serve as useful information for Korea pharmaceutical companies preparing GMP inspection by PIC/S member states and also for MFDS to derive global GMP inspection guidelines in the future.
Keywords : GMP inspection, deficiencies, warning letter, EudraGMDP database

February 2019, 63 (1)
Full Text(PDF) Free

Social Network Service

Cited By Articles
  • CrossRef (0)